
Eli Lilly and DICE Therapeutics have announced a definitive agreement for Lilly to acquire DICE, a biopharmaceutical company focusing on …
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand

